Zobrazeno 1 - 10
of 45
pro vyhledávání: '"Giuseppe Lo Russo"'
Autor:
Arsela Prelaj, Edoardo Gregorio Galli, Vanja Miskovic, Mattia Pesenti, Giuseppe Viscardi, Benedetta Pedica, Laura Mazzeo, Achille Bottiglieri, Leonardo Provenzano, Andrea Spagnoletti, Roberto Marinacci, Alessandro De Toma, Claudia Proto, Roberto Ferrara, Marta Brambilla, Mario Occhipinti, Sara Manglaviti, Giulia Galli, Diego Signorelli, Claudia Giani, Teresa Beninato, Chiara Carlotta Pircher, Alessandro Rametta, Sokol Kosta, Michele Zanitti, Maria Rosa Di Mauro, Arturo Rinaldi, Settimio Di Gregorio, Martinetti Antonia, Marina Chiara Garassino, Filippo G. M. de Braud, Marcello Restelli, Giuseppe Lo Russo, Monica Ganzinelli, Francesco Trovò, Alessandra Laura Giulia Pedrocchi
Publikováno v:
Frontiers in Oncology, Vol 12 (2023)
IntroductionArtificial Intelligence (AI) methods are being increasingly investigated as a means to generate predictive models applicable in the clinical practice. In this study, we developed a model to predict the efficacy of immunotherapy (IO) in pa
Externí odkaz:
https://doaj.org/article/c99b6a5fcaed44e39c58687c3976c7f5
Autor:
Diego Signorelli, Patrizia Ghidotti, Claudia Proto, Marta Brambilla, Alessandro De Toma, Roberto Ferrara, Giulia Galli, Monica Ganzinelli, Giuseppe Lo Russo, Arsela Prelaj, Mario Occhipinti, Giuseppe Viscardi, Valentina Capizzuto, Francesca Pontis, Ilaria Petraroia, Anna Maria Ferretti, Mario Paolo Colombo, Valter Torri, Gabriella Sozzi, Marina Chiara Garassino, Elena Jachetti, Orazio Fortunato
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
PD-L1 in tumor cells is the only used biomarker for anti PD1/PD-L1 immune-checkpoints inhibitors (ICI) in Non Small Cell Lung Cancer (NSCLC) patients. However, this parameter is inaccurate to predict response, especially in patients with low tumor PD
Externí odkaz:
https://doaj.org/article/ab5e8307dc3647979bd096212900848c
Autor:
Marta Brambilla, Giuseppe Lo Russo, Roberto Ferrara, Sara Manglaviti, Marina Chiara Garassino, Mario Occhipinti
Publikováno v:
Exploration of Targeted Anti-tumor Therapy, Vol 1, Iss 6, Pp 427-433 (2020)
Hyperprogressive disease (HPD) is a novel pattern of response during immunotherapy treatment. Several retrospective studies have evaluated its prevalence among various cancer types and, in particular, in non-small cell lung cancer patients, based on
Externí odkaz:
https://doaj.org/article/98d68b26669d4816b5dbb0f1ebae41f6
Autor:
Arsela Prelaj, Mattia Boeri, Alessandro Robuschi, Roberto Ferrara, Claudia Proto, Giuseppe Lo Russo, Giulia Galli, Alessandro De Toma, Marta Brambilla, Mario Occhipinti, Sara Manglaviti, Teresa Beninato, Achille Bottiglieri, Giacomo Massa, Emma Zattarin, Rosaria Gallucci, Edoardo Gregorio Galli, Monica Ganzinelli, Gabriella Sozzi, Filippo G. M. de Braud, Marina Chiara Garassino, Marcello Restelli, Alessandra Laura Giulia Pedrocchi, Francesco Trovo'
Publikováno v:
Cancers, Vol 14, Iss 2, p 435 (2022)
(1) Background: In advanced non-small cell lung cancer (aNSCLC), programmed death ligand 1 (PD-L1) remains the only biomarker for candidate patients to immunotherapy (IO). This study aimed at using artificial intelligence (AI) and machine learning (M
Externí odkaz:
https://doaj.org/article/ad41281b62b04e7a9b1e3186536ae12f
Autor:
Arsela Prelaj, Chiara Carlotta Pircher, Giacomo Massa, Valentino Martelli, Giulia Corrao, Giuseppe Lo Russo, Claudia Proto, Roberto Ferrara, Giulia Galli, Alessandro De Toma, Carlo Genova, Barbara Alicja Jereczek-Fossa, Filippo de Braud, Marina Chiara Garassino, Sara Elena Rebuzzi
Publikováno v:
Cancers, Vol 13, Iss 6, p 1300 (2021)
First-line immune-checkpoint inhibitor (ICI)-based therapy has deeply changed the treatment landscape and prognosis in advanced non-small cell lung cancer (aNSCLC) patients with no targetable alterations. Nonetheless, a percentage of patients progres
Externí odkaz:
https://doaj.org/article/d7f79882c14f4b6b870b9127d66a56e3
Autor:
Federico Nichetti, Francesca Ligorio, Emma Zattarin, Diego Signorelli, Arsela Prelaj, Claudia Proto, Giulia Galli, Antonio Marra, Giulia Apollonio, Luca Porcu, Filippo de Braud, Giuseppe Lo Russo, Roberto Ferrara, Marina Chiara Garassino
Publikováno v:
Cancers, Vol 12, Iss 1, p 67 (2019)
PD-1 pathway blockade has been shown to promote proatherogenic T-cell responses and destabilization of atherosclerotic plaques. Moreover, preclinical evidence suggests a potential synergy of antiplatelet drugs with immune checkpoint inhibitors (ICIs)
Externí odkaz:
https://doaj.org/article/86cff2aa81044bd7abf5d9e8dcce6098
Autor:
Giulia Galli, Paola Antonia Corsetto, Claudia Proto, Giuseppe Lo Russo, Monica Ganzinelli, Eliana Rulli, Lorenzo Legramandi, Daniele Morelli, Roberto Ferrara, Arsela Prelaj, Diego Signorelli, Alessandro De Toma, Marta Brambilla, Mario Occhipinti, Sara Manglaviti, Mattia Boeri, Antonia Martinetti, Andrea Vingiani, Mario Paolo Colombo, Angela Maria Rizzo, Valter Torri, Filippo de Braud, Sabina Sangaletti, Antonio Sica, Marina Chiara Garassino
Publikováno v:
Clinical Lung Cancer. 23:e489-e499
Lipid metabolism impacts immune cell differentiation, activation, and functions, modulating inflammatory mediators, energy homeostasis, and cell membrane composition. Despite preclinical evidence, data in humans lack concerning tumors and immunothera
Autor:
Caterina Zanella, Alberto Giovanni Leone, Luca Zambelli, Achille Bottiglieri, Luca Canziani, Marta Brambilla, Giuseppe Lo Russo, Marco Platania, Filippo De Braud, Mario Occhipinti
Publikováno v:
Tumori Journal. 108:NP11-NP14
Paraneoplastic syndromes occur in about 0.1% of patients affected by neoplastic diseases. In some types of tumors, such as Small Cell Lung Cancer (SCLC), Thymoma, and particular forms of Plasmacytoma, the association with Paraneoplastic Neurological
Autor:
Laura Botta, Giulia Galli, Annalisa Trama, Marcello Tiseo, Claudia Proto, Ugo Pastorino, Giulia Pasello, Roberto Ferrara, Adele Busico, Martina Imbimbo, Arsela Prelaj, Diego Signorelli, Gemma Gatta, Giuseppe Lo Russo, Monica Ganzinelli, Elena Tamborini, Alessandro De Toma, Alessandra Fabbri, Marina Chiara Garassino, Filippo de Braud
Publikováno v:
Transl Lung Cancer Res
BACKGROUND: Malignant pleural mesothelioma (MPM) is an aggressive tumor but approximately 12% of patients survive more than 3 years. The biological differences underlying better outcomes are not known. Several targeted agents and immunotherapy have b
Autor:
Emma Zattarin, Sara Manglaviti, Giulia Apollonio, Teresa Beninato, Laura Mazzeo, Giacomo Massa, Achille Bottiglieri, Edoardogregorio Galli, Alessandro De Toma, Mario Occhipinti, Marta Brambilla, Roberto Ferrara, Monica Ganzinelli, Claudia Proto, Marina Chiara Garassino, Filippo de Braud, Giuseppe Lo Russo, Arsela Prelaj
Patients affected by inoperable lung cancer, due to great extension or to the presence of metastases, are currently treated with intravenous drugs that act on immune system activation alone or in combination with chemotherapy as first-line treatment.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c1b99ffd971ad1f80421b1e53de9e636
http://hdl.handle.net/11311/1220881
http://hdl.handle.net/11311/1220881